| abstract |
Compounds represented by the general formula (I) or salts thereof, and medicines containing the same: (I) [wherein W is W<A>-A<1>-W<B>- (wherein W<A> is optionally substituted aryl or the like; A<1> is -NR<1>-, a single bond, -C(O)-, or the like; and W<B> is optionally substituted arylene or the like); R is a single bond, -NH-, -OCH2-, alkenylene, or the like; X is -C(O)-, -CH2-, or the like; and M is, e.g., a group represented by the general formula (iii): (iii) (wherein R<11>, R<12>, and R<13> are each independently hydrogen, hydroxyl, amino, halogeno, or the like; R<14> is hydrogen or lower alkyl; Y is -CH2-O- or the like; Z is optionally substituted arylene or the like; A<2> is a single bond or the like; and R<10>is hydroxyl or lower alkoxy)]. The compounds or the salts selectively inhibit the binding of cell adhesion molecules to VLA-4 and exhibit high oral absorbability, thus being useful as preventive and/or therapeutic drugs for inflammatory diseases, autoimmune diseases, cancerous metastasis, bronchial asthma, nasal occlusion, diabetes, and so on. |